Over the last three decades, multiple clinical studies have targeted NRF2, but none have focused on FLT3 mutant AML [41,42], although the targeting of NRF2 and antioxidants has been implicated in leukemic stem cell (LSC) depletion and has shown potential for further study [43,44]. This evidence concerns the gene FLT3 and acute myeloid leukemia.